Literature DB >> 16611855

Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2.

Cheryl E Rockwell1, Natasha T Snider, Jerry T Thompson, John P Vanden Heuvel, Norbert E Kaminski.   

Abstract

2-Arachidonyl glycerol (2-AG) is an endogenous arachidonic acid derivative that binds cannabinoid receptors CB1 and CB2 and is hence termed an endocannabinoid. 2-AG also modulates a variety of immunological responses, including expression of the autocrine/paracrine T cell growth factor interleukin (IL)-2. The objective of the present studies was to determine the mechanism responsible for IL-2 suppression by 2-AG. Because of the labile properties of 2-AG, 2-AG ether, a nonhydrolyzable analog of 2-AG, was also used. Both 2-AG and 2-AG ether suppressed IL-2 expression independently of CB1 and CB2, as demonstrated in leukocytes derived from CB1/CB2-null mice. Moreover, we demonstrated that both 2-AG and 2-AG ether treatment activated peroxisome proliferator-activated receptor gamma (PPARgamma), as evidenced by forced differentiation of 3T3-L1 cells into adipocytes, induction of aP2 mRNA levels, and activation of a PPARgamma-specific luciferase reporter in transiently transfected 3T3-L1 cells. Consequently, the putative role of PPARgamma in IL-2 suppression by 2-AG and 2-AG ether was examined in Jurkat T cells. Concordant with PPARgamma involvement, the PPARgamma-specific antagonist 2-chloro-5-nitro-N-(4-pyridyl)-benzamide (T0070907) blocked 2-AG- and 2-AG ether-mediated IL-2 suppression. Likewise, 2-AG suppressed the transcriptional activity of two transcription factors crucial for IL-2 expression, nuclear factor of activated T cells and nuclear factor kappaB, in the absence but not in the presence of T0070907. 2-AG treatment also induced PPARgamma binding to a PPAR response element in activated Jurkat T cells. Together, the aforementioned studies identify PPARgamma as a novel intracellular target of 2-AG, which mediates the suppression of IL-2 by 2-AG in a manner that is independent of CB1 and/or CB2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611855     DOI: 10.1124/mol.105.019117

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  69 in total

1.  15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma.

Authors:  Priyadarshini Raman; Barbara L F Kaplan; Jerry T Thompson; John P Vanden Heuvel; Norbert E Kaminski
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Tempo and mode in the endocannaboinoid system.

Authors:  John M McPartland; Ryan W Norris; C William Kilpatrick
Journal:  J Mol Evol       Date:  2007-08-04       Impact factor: 2.395

4.  A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio).

Authors:  J M McPartland; Michelle Glass; Isabel Matias; Ryan W Norris; C William Kilpatrick
Journal:  Mol Genet Genomics       Date:  2007-01-26       Impact factor: 3.291

5.  Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.

Authors:  Christine Börner; Michal Smida; Volker Höllt; Burkhart Schraven; Jürgen Kraus
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 6.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

7.  Alleviation of Neuropathology by Inhibition of Monoacylglycerol Lipase in APP Transgenic Mice Lacking CB2 Receptors.

Authors:  Jian Zhang; Chu Chen
Journal:  Mol Neurobiol       Date:  2017-07-21       Impact factor: 5.590

Review 8.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

Review 9.  Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases.

Authors:  Amber Cintosun; Irene Lara-Corrales; Elena Pope
Journal:  Clin Drug Investig       Date:  2020-04       Impact factor: 2.859

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.